Filing Flows › UroGen Pharma (URGN) › Q3 2026
UroGen Pharma (URGN) Q3 2026 earnings results (third quarter 2026)
10-Q filed Nov 4, 2026
UroGen Pharma (URGN) reported revenue of $89.0M for the third quarter 2026 (Q3 2026), +224% from a year earlier and +23% from the quarter before. Operating margin was 9.4%, net loss $1.5M (1.6% of revenue).
UroGen Pharma, Q3 2026: revenue $89.0M (+224% year over year), operating margin 9.4%, net loss $1.5M, operating cash flow −$15.2M. The chart follows the revenue to costs, profit and cash.
| Q3 2026 | Amount | Q/Q | Y/Y |
|---|---|---|---|
| Revenue | $89.0M | +23% | +224% |
| Operating profit | $8.3M | 75× | — |
| Net earnings | −$1.5M | — | — |
| Operating cash flow | −$15.2M | — | — |
What changed
Revenue was $89.0M in Q3 2026, up 224% year over year and up 23% from the previous quarter. Zusduri was the largest line at 76% of revenue. Zusduri added $66.3M year over year (up 3725%), 108% of the total change. Jelmyto declined 18%.
Gross margin was 91.6%, up 3.5 points from Q3 2025. Operating profit was $8.3M, a 9.4% margin (up 109.0 points year over year). Operating expenses grew 42% against revenue growth of 224%. The fastest-growing cost line was Research & development (+85%). The quarter ended with a net loss of $1.5M, narrower than the previous quarter's $14.4M loss. Net interest and other expense of $8.8M was the main reason.
Operating cash flow was −$15.2M. Non-cash charges added back $100K of depreciation and amortization and $6.2M of share-based compensation. Working capital and other items used $20.1M. Capital expenditures of $72K exceeded it, leaving free cash flow of −$15.3M.
Questions
What was UroGen Pharma's revenue in the third quarter 2026?
UroGen Pharma (URGN) reported revenue of $89.0M for the third quarter 2026 (Q3 2026), +224% from a year earlier and +23% from the quarter before.
Was UroGen Pharma profitable in the third quarter 2026?
Operating profit was $8.3M (9.4% of revenue) and net loss $1.5M.
Source: UroGen Pharma 10-Q on SEC EDGAR.